Loading...
•
Jun 30, 2024
Matinas BioPharma Q2 2024 Earnings Report
Matinas BioPharma's financial position remained stable with a slight decrease in net loss and continued focus on partnership opportunities for MAT2203.
Key Takeaways
Matinas BioPharma reported no revenue for Q2 2024, with a net loss of $5.7 million, slightly improved from $6.1 million in Q2 2023. The company is actively pursuing partnership opportunities for MAT2203 and signed a non-binding term sheet for global licensing rights.
Signed a non-binding term sheet granting global rights to develop and commercialize oral MAT2203 for invasive aspergillosis.
31 patients have enrolled in the MAT2203 Compassionate/Expanded Use Access Program, with 6 additional patients under evaluation.
Completed additional LNC platform work in inflammation and oncology and evaluating next steps.
Cash, cash equivalents and marketable securities totaled $14.3 million as of June 30, 2024.